Mark Mcdade Net Worth

The estimated Net Worth of Mark Mcdade is at least $21.6 Миллион dollars as of 12 June 2019. Mark Mcdade owns over 3,000 units of PDL Biopharma Inc stock worth over $21,636,000 and over the last 21 years Mark sold PDLI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Mcdade PDLI stock SEC Form 4 insiders trading

Mark has made over 42 trades of the PDL Biopharma Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Mark exercised 3,000 units of PDLI stock worth $10,818,000 on 12 June 2019.

The largest trade Mark's ever made was exercising 20,000 units of PDL Biopharma Inc stock on 8 January 2007 worth over $166,000. On average, Mark trades about 6,130 units every 77 days since 2003. As of 12 June 2019 Mark still owns at least 6,000 units of PDL Biopharma Inc stock.

You can see the complete history of Mark Mcdade stock trades at the bottom of the page.

What's Mark Mcdade's mailing address?

Mark's mailing address filed with the SEC is C/O AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE, CA, 94005-1884.

Insiders trading at PDL Biopharma Inc

Over the last 22 years, insiders at PDL Biopharma Inc have traded over $45,966,964 worth of PDL Biopharma Inc stock and bought 12,693,393 units worth $32,804,545 . The most active insiders traders include Point Capital L.P.O'shea Ro..., Faheem Hasnain и Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of $245,074,578. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth $383,475.

What does PDL Biopharma Inc do?

Complete history of Mark Mcdade stock trades at Aimmune Therapeutics Inc, Cytokinetics Inc, Five Prime Therapeutics Inc и PDL Biopharma Inc

PDL Biopharma Inc executives and stock owners

PDL Biopharma Inc executives and other stock owners filed with the SEC include:

• Dominique Monnet,
  President, Chief Executive Officer, Director
• Christopher Stone,
  Vice President, General Counsel, Secretary
• Edward Imbrogno,
  Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
• John McLaughlin,
  Director
• David Gryska,
  Independent Director
• Elizabeth O'Farrell,
  Chairperson of the Board
• Natasha Hernday,
  Independent Director
• Alan Bazaar,
  Independent Director
• Danny J Jr. Hart,
  Assoc Genl Counsel/Asst Sec
• Samuel R Saks,
  Director
• Jody S Lindell,
  Director
• Paul R Edick,
  Director
• Harold E Selick,
  Director
• Paul W Sandman,
  Director
• Peter S Garcia,
  Vice President, CFO
• Steffen Pietzke,
  Controller and CAO
• Shlomo Yanai,
  Director
• Jill M. Jene,
  VP, Business Development
• Christine R Larson,
  VP & Chief Financial Officer
• Joseph Iii Klein,
  Director
• Karen J Wilson,
  VP of Finance & PAO
• Mark Anthony Mc Camish,
  SVP & CMO
• Brett L Schmidli,
  SVP, Technical Operations
• Gary A Lyons,
  Director
• Andrew Guggenhime,
  SVP & Chief Financial Officer
• Faheem Hasnain,
  President & CEO
• Francis Willard Sarena,
  Exec Dir/Chief Legal Off/Secy
• Herb Cross,
  Corp Controller/Prin Acctg Off
• Richard /Ca/ Murray,
  Sr. VP & CSO
• Steven E Benner,
  SVP and Chief Medical Officer
• Bradford S Goodwin,
  Director
• Laurence Jay Korn,
  Chairman of the Board
• Karen A Dawes,
  Director
• Jaisim Shah,
  Vice President, Marketing
• Jon S Saxe,
  Director
• L Patrick Gage,
  Director
• Glen Y Sato,
  SVP and CFO
• Cynthia Lynn Shumate,
  VP Legal Affrs, Secy & CCO
• Cary L Queen,
  Senior Vice President
• Peter H Calcott,
  VP, Quality & Compliance
• Laurie C Torres,
  VP, Human Resources
• David Iwanicki,
  VP, Sales & Sales Operations
• Mark Mcdade,
  Chief Executive Officer
• Robert Michael Ii Savel,
  SVP Technical Operations
• Samuel Broder,
  Director
• George Jue,
  VP, Fin & Corp. Controller
• Max Link,
  Director
• Sergio Garcia Rodriguez,
  VP, Legal and General Counsel
• Lyn D Olson,
  VP, Quality and Compliance
• Douglas O Ebersole,
  SVP, Legal & Corp Development
• George M Gould,
  Director
• Jurgen Drews,
  Director
• Behrooz Najafi,
  V.P. IS and Corporate Services
• Corine Klingbell,
  VP, Preclinical Development
• William R Benjamin,
  VP, Research & Clinical Tech
• Frances G Charlson,
  VP, Human Resources
• Patrick M Caldwell,
  VP, Finance and Controller
• Mark P Backer,
  VP, Technical Development
• David Montez,
  Controller and CAO
• Fred Frank,
  Director
• Bruce Tomlinson,
  Chief Financial Officer
• Caroline J Krumel,
  Vice President of Finance
• Point Capital L.P.O'shea Ro...,